Patents by Inventor Danielle M. GREENAWALT

Danielle M. GREENAWALT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20230279114
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
    Type: Application
    Filed: January 30, 2023
    Publication date: September 7, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
  • ANTI-CCR8 ANTIBODIES FOR TREATING CANCER
    Publication number: 20230119066
    Abstract: This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.
    Type: Application
    Filed: March 22, 2021
    Publication date: April 20, 2023
    Inventors: Ruth Yin-Zong Lan, Olufemi A. Adelakun, Ishita Barman, Joseph Campbell, SJ Jian Zhe Diong, Felix Findeisen, Danielle M. Greenawalt, Renu Jain, Amy D. Jhatakia, John K. Lee, Peter S.K. Lee, Linda Liang, Kai Lu, Bryan McDonald, Paul Mesko, Arvind Rajpal, Sharmila Sambanthamoorthy, Mark J. Selby, Nathan O. Siemers, Pavel Strop, Gaby A. Terracina, Xi-Tao Wang
  • Methods of treating a tumor using an anti-PD-1 antibody
    Patent number: 11566073
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 31, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robin Edwards, William J. Geese, Danielle M. Greenawalt
  • METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20200109204
    Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT